{"original": "In relation to COVID-19, Friman et al. investigated the off-target effects of the broad-spectrum antiviral Remdesivir, one of the first drugs to be repurposed for use during the pandemic. Remdesivir was evaluated using thermal proteome profiling in a HepG2 cellular thermal shift assay, alongside the drug hydroxychloroquine, which has been subject to controversy. The study identified TRIP13 as a potential off-target for Remdesivir.\n\n\nIt ", "sampled": "In relation to COVID-19, Friman et investigation. investigated this off-target effects about the broad-spectrum antiviral Remdesivir, one as this first drugs to be repurposed for use during the pandemic. Remdesivir was evaluated using thermal proteome profiling in a HepG2 cellular thermal shift appraisal, alongside the drug hydroxychloroquine, which has been subject to controversy. The study identified TRIP13 as a potential off-target for Remdesivir.\n\n\nIt ", "replacement_keys": [11, 2, 83, 19, 33, 34, 38, 68, 14], "original_crit": -1.2507908344268799, "sampled_crit": -1.8911057710647583, "original_llm_likelihood": 0.49, "sampled_llm_likelihood": 0.31}